Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy.
MRI
diffusion weighted magnetic resonance imaging (DWI)
imaging biomakers
muscle invasive bladder cancer (MIBC)
neoadjuavant chemotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
06
2022
accepted:
29
09
2022
entrez:
1
12
2022
pubmed:
2
12
2022
medline:
2
12
2022
Statut:
epublish
Résumé
This study aims to determine local treatment response and long-term survival outcomes in patients with localised muscle-invasive bladder cancer (MIBC) patients receiving neoadjuvant chemotherapy (NAC) using diffusion-weighted MRI (DWI) and apparent diffusion coefficient (ADC) analysis. Patients with T2-T4aN0-3M0 bladder cancer suitable for NAC were recruited prospectively. DWI was performed prior to NAC and was repeated following NAC completion. Conventional response assessment was performed with cystoscopy and tumour site biopsy. Response was dichotomised into response (<T2) or poor response (≥T2). Patients proceeded to either radical cystectomy or chemo-radiotherapy as standard of care. Tumour ADC values were calculated for all b-values (ADC Forty-eight patients (96 DWI) were evaluated. NAC response was associated with significant increase in mean ΔADC and %ΔADC compared to poor response (ΔADC Quantitative ADC analysis can successfully identify NAC response and improved long-term clinical outcomes. Multi-centre validation to assess reproducibility and repeatability is required before testing within clinical trials to inform MIBC treatment decision making. We successfully demonstrated that measured change in DWI can successfully identify NAC response and improved long-term survival outcomes.
Identifiants
pubmed: 36452501
doi: 10.3389/fonc.2022.961393
pmc: PMC9702046
doi:
Types de publication
Journal Article
Langues
eng
Pagination
961393Informations de copyright
Copyright © 2022 Hafeez, Koh, Jones, Ghzal, D’Arcy, Kumar, Khoo, Lalondrelle, McDonald, Thompson, Scurr, Sohaib and Huddart.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Magn Reson Med. 2014 Jan;71(1):411-20
pubmed: 23408505
J Urol. 2000 Jun;163(6):1693-6
pubmed: 10799162
Nat Rev Clin Oncol. 2017 Mar;14(3):169-186
pubmed: 27725679
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1048-56
pubmed: 24661658
J Magn Reson Imaging. 2017 Nov;46(5):1281-1288
pubmed: 28199039
Ther Adv Urol. 2021 Aug 25;13:17562872211039583
pubmed: 34457041
Eur Radiol. 2011 Oct;21(10):2178-86
pubmed: 21688007
Front Oncol. 2022 Aug 17;12:990176
pubmed: 36059618
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
Eur Urol. 2010 Jan;57(1):60-70
pubmed: 19740595
Clin Radiol. 2007 Nov;62(11):1087-93
pubmed: 17920868
Gynecol Oncol. 2008 Nov;111(2):213-20
pubmed: 18774597
Radiology. 2009 Apr;251(1):112-21
pubmed: 19332849
Clin Cancer Res. 2017 Nov 1;23(21):6487-6497
pubmed: 28760909
BMC Med. 2013 Apr 10;11:104
pubmed: 23574966
Eur Urol. 2021 Jul;80(1):12-15
pubmed: 33653635
Transl Androl Urol. 2017 Apr;6(2):331-335
pubmed: 28540249
Urology. 2010 Feb;75(2):387-91
pubmed: 19914691
Neoplasia. 2009 Feb;11(2):102-25
pubmed: 19186405
Radiology. 2018 Feb;286(2):502-511
pubmed: 29206594
Urol Oncol. 2014 Nov;32(8):1166-71
pubmed: 24962659
Eur Radiol. 2015 Jul;25(7):2033-40
pubmed: 25605133
Eur Urol Oncol. 2021 Apr;4(2):310-314
pubmed: 31563523
J Magn Reson Imaging. 2014 Jan;39(1):172-8
pubmed: 23589321
Eur Urol. 2021 Mar;79(3):364-371
pubmed: 32814637
Eur Urol. 2020 May;77(5):636-643
pubmed: 31882281
BJU Int. 2018 Nov;122(5):744-753
pubmed: 29727910
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Abdom Radiol (NY). 2021 Jun;46(6):2712-2721
pubmed: 33547919
Eur Urol Oncol. 2022 Apr 8;:
pubmed: 35410825
J Clin Oncol. 2019 Jun 20;37(18):1547-1557
pubmed: 31059311
World J Radiol. 2014 Jun 28;6(6):344-54
pubmed: 24976935
Ann Oncol. 2017 Oct 01;28(10):2458-2463
pubmed: 28945843
J Pers Med. 2021 Mar 23;11(3):
pubmed: 33806972
Br J Cancer. 2015 May 12;112(10):1626-35
pubmed: 25897675
Eur Urol Focus. 2020 Jul 15;6(4):642-649
pubmed: 31708469
Oncologist. 2016 Jun;21(6):708-15
pubmed: 27053504
BJU Int. 2019 Sep;124(3):532-544
pubmed: 31077629
Eur Radiol. 2010 Feb;20(2):491-6
pubmed: 19657643
Radiology. 2011 Oct;261(1):182-92
pubmed: 21828186
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Eur Urol. 2018 Nov;74(5):597-608
pubmed: 30017405
J Magn Reson Imaging. 2016 Sep;44(3):521-40
pubmed: 26892827
Eur Urol. 2016 Jul;70(1):75-82
pubmed: 26803478
Eur Urol. 2006 Apr;49(4):698-703
pubmed: 16464531
Nat Rev Urol. 2022 Jan;19(1):37-46
pubmed: 34508246
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
J Clin Oncol. 2010 Nov 20;28(33):4912-8
pubmed: 20956620
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e21-7
pubmed: 22414281
Radiology. 2008 Sep;248(3):894-900
pubmed: 18710982
Front Oncol. 2021 May 13;11:619893
pubmed: 34055600
N Engl J Med. 2012 Apr 19;366(16):1477-88
pubmed: 22512481
Eur J Radiol. 2017 Oct;95:46-55
pubmed: 28987698
Eur Urol. 2018 Sep;74(3):294-306
pubmed: 29755006